Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Alzchem shares slide sharply after quarterly results and impairment announcement

    Alzchem shares fell by double digits at times and dropped 8.8 percent on Friday to €147.40, the lowest level since early February, breaking the sideways trading that had persisted since summer. The company confirmed its forecast for 2026 when presenting the quarterly figures, while an accelerated write-down for a new nitroguanidine plant is causing charges. Berenberg analyst Gerhard Orgonas expects average market estimates for operating profit (EBIT) to be revised down by around four to five percent. » More on finanzen.net


  • Alzchem: quarterly profit shrinks despite slight revenue increase

    In the third quarter Alzchem’s revenue rose slightly to almost €140.0 million (previous year approx. €137.0 million), while EBITDA fell from €29.7 million to €28.7 million and the margin declined by 1.2 percentage points to 20.5%. Profit decreased from €16.3 million to €13.5 million. The company confirmed its full-year guidance of around €600 million in revenue and about €126 million in EBITDA. In the first nine months, revenues increased 4% to €443.8 million and EBITDA rose 8% to €93.2 million; results were weighed down by higher energy and raw material costs as well as start-up expenses for new capacities. » More on finanzen.net


  • Alzchem Group approves share buyback of up to €20 million

    The management board of Alzchem Group, with the supervisory board’s approval, has decided to repurchase up to 125,000 shares over a period of up to 12 months with a total volume of up to €20 million. The shares may be used as acquisition currency, for employee participation programmes, or for cancellation and capital reduction. The buyback will start after the publication of the Q3 figures on 29 October 2026 and after the expiry of the closed period; exact details will be announced before the start. » More on finanzen.net


  • Alzchem Group to publish quarterly results for period ended 30 September 2026 on 29 October 2026

    Alzchem Group will publish results for the quarter ended 30 September 2026 on 29 October 2026. One analyst expects on average earnings per share of EUR 1.43 (prior year EUR 1.61). Two analysts see revenue averaging EUR 143.4m, an increase of 4.5% from EUR 137.3m in the prior year. For the fiscal year, nine analysts forecast on average an EPS of EUR 6.54 and revenue of EUR 608.7m (prior year EUR 6.28 and EUR 562.1m). » More on finanzen.net


  • Board member Andreas Niedermaier buys 260 Alzchem Group shares at EUR 153.50 each

    On 4 August 2026, board member Andreas Niedermaier acquired 260 Alzchem Group shares at EUR 153.50 each; the transaction was reported on 5 August 2026. The report briefly pushed the stock in FSE trading up to EUR 158.00, a rise of around 1.6 percent. Market capitalization is currently about EUR 1.59 billion with 10,123,624 shares in free float. Previously, on 31 July 2026, Niedermaier had already added 124 shares at EUR 161.40 to his portfolio. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics
In 2024, AlzChem has already paid €1.30 in dividends. The last payout was in May 2024.

Financials

In the last quarter, AlzChem had revenue of €139.88M and net profit of €13.5M
(EUR) September 2026
YoY
Revenue 139.88M 1.91%
Gross profit 92.52M 109.23%
Net profit 13.5M 17.12%
EBITDA 29.63M 3.00%

Fundamentals

Metric Value
Market capitalization
€1.62B
Number of shares
10.12M
52-week high/low
€210.60 - €123.20
Dividends No
Beta
0.55
P/E ratio
-
PEG ratio
-
P/B ratio
-
P/S ratio
-

Company profile

AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand. It also provides fine and specialty chemicals, including products based on calcium carbide, calcium cyanamide, hydrogen cyanamide, dicyandiamide, guanidine, guanamines, and nitroguanidine, as well as aromatic and aliphatic nitriles; calcium cyanamide under the PERLKA name; germicide for use in pig pens under the ALZOGUR name; plant growth regulators under the Dormex and Sitofex name; and plant protection additives under the BREAK-THRU name. In addition, the company offers products for use in hot metal desulfurization and secondary metallurgy applications; and technical gases. Further, it provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services. AlzChem Group AG was founded in 1908 and is based in Trostberg, Germany.

Name
AlzChem
CEO
Andreas Niedermaier
Headquarters Trostberg, bv
Germany
Website
Sector
Materials
Industry
Chemicals
IPO
08/12/2004
Employees 1,680

Ticker symbols

Exchange Symbol
XETRA
ACT.DE
Pnk
ALZCF
Frankfurt
ACT.F
Düsseldorf
ACT.DU
London
0ACT.L
SIX
SFP1.SW
München
ACT.MU
🍪

Parqet  uses cookies. Learn more